QbD and Subjective Risk Assessments

Date: 08 January 2020

Time: 15:00 (GMT), 16.00 (CET), 10.00 (ET), 7.00 (PT)

Tutors: Dr Paul Murray

Successful risk assessment is a fundamental aspect of Quality by Design (QbD), however, risk analysis is a subjective process and is open to human bias and inaccuracy. This webinar will introduce the QbD process and the FDA’s objective with QbD, focussing on risk assessment. Different risk assessment tools will be discussed and a case study, showing how a well carried out QbD risk assessment can ensure consistent quality, will be presented.

Who should listen:

Chemists, engineers, analysts and formulators in pharmaceutical development. Anyone involved or interested in the risk assessment process.

This webinar will be delivered by Dr Paul Murray, Paul Murray Catalysis Consulting.


15.00 GMT (UK, Lisbon)
16.00 CET (Paris, Madrid, Frankfurt etc)
10.00 ET (New York, Boston)
7.00 PT (San Francisco, LA)

If you’d like to learn more, Paul is also a tutor on the following 3-day course:

QbD in Pharmaceutical Development

Book Now